Recruiting
Phase 2

Obicetrapib

Sponsor:

NewAmsterdam Pharma

Code:

NCT07794670

Conditions

Preclinical Alzheimer's Disease

Eligibility Criteria

Sex: All

Age: 55 - 70+

Healthy Volunteers: Not accepted

Interventions

Obicetrapib 10 mg

Matching placebo tablets

Study Details

Brief summary:

A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease

Conditions

Preclinical Alzheimer's Disease

Study ID

NCT07794670

Start date

Sep, 2026

Status verified date

Sep, 2026

Completion date

May, 2029

Anticipated

Primary completion date

Sep, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 55 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • participants with preclinical AD

Exclusion Criteria:

  • APOE genotype not meeting protocol-defined eligibility criteria

Study Design

Enrollment

400 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

placebo comparator: Placebo

Placebo

experimental: Obicetrapib

10 mg Obicetrapib, once daily

Interventions

Obicetrapib 10 mg

once daily 10 mg Obicetrapib tablet

Matching placebo tablets

matching placebo tablet

Primary outcome measure

  • Change from Baseline to Week 52 in ptau 217 [ Time Frame: Baseline, Week 52 ]

Central Contacts and Locations

Locations

K2 Medical Research

Recruiting

Nashville, Tennessee, United States, 37204

Contacts

Victoria Marsh

615-208-K2K2 (5252)victoria.marsh@k2med.com

More Information

Sponsor

NewAmsterdam Pharma

Last update posted

Sep 28, 2026

Last verified

Sep, 2026

Keywords

  • Preclinical
  • Alzheimer's Disease
  • ptau 217
  • ApoE

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-29. This information was provided to ClinicalTrials.gov by NewAmsterdam Pharma on 2026-09-28. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.